Document is current
Any future updates will be listed below
-
Authors
Graham, Sarah
Sartorius, Benn
Snelling, Tom
Homaira, Nusrat
Newall, Anthony T.
Binks, Michael
Lau, Colleen
Hughes, Catherine
McHugh, Lisa
-
Funding
Funding for this research was provided by:
Medical Research Future Fund (MRF1195153)
National Health and Medical Research Council (GNT1193826)
National Health and Medical Research Council (GNT2016407)
- License Information
-
More Information
Article History
Received: 8 September 2025
Accepted: 8 January 2026
First Online: 22 January 2026
Declarations
:
: Unconditional ethics approval was attained for this project by the Human Research Ethics Committees (HREC) from The University of Queensland and Queensland Health, approval number HREC/2023/MNHA/96960. A waiver of individual informed consent was requested from and granted by The University of Queensland HREC due to the large size of the study and the use of de-identified data. The study was conducted in accordance with the ethical principles of the Declaration of Helsinki.
: Not applicable.
: N.H. has at times received consultation fees from Sanofi, Pfizer and Merck Sharp & Dohme Australia, and is a chief investigator of an industry-sponsored study on RSV complications. C.H. is employed by the Immunisation Foundation of Australia, which has received unrestricted educational grants from Sanofi, Pfizer, and GSK to support RSV awareness activities. S.G., B.S., T.S., A.N, M.B., C.L., and L.Mc. have no potential conflicts of interest to declare.C.H. is employed by the Immunisation Foundation of Australia, which has received unrestricted educational grants from Sanofi, Pfizer, and GSK to support RSV awareness activities.S.G., B.S., T.S., A.N, M.B., C.L., and L.Mc. have no potential conflicts of interest to declare.
: .
